Zusammenfassung
Weltweit beschäftigen sich Arbeitsgruppen mit der Aufklärung möglicher Mechanismen der Tumorentstehung. Aus der Molekulargenetik kamen in den letzten Jahren eine Vielzahl von Informationen, welche zur Diskussion von Onkogenen als zentrale Initiatoren der malignen Transformation führten (Weinberg 1984; Slaman et al. 1984).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Atkins NB (1974) Chromosomes in human malignant tumors: a review and assessment. Germin J (ed) Chromosomes and cancer. Wiley, New York, pp 375–412
Baldwin RW, Buyers VS (1986) Monoclonal antibody targeting of anti-cancer agents. Semin Immunopathol 9: 39–50
Barrack ER, Bujnovsky P, Walsh PC (1983) Subcellular distribution of androgen receptors in human normal, benign hyperplastic and malignant prostatic tissue: Characterization of nuclear salt-resistent receptors, Cancer Res 43: 1107–1116
Bishop JM (1981) oncogenes. Sci Am 246: 68–78 (Cell 23, 5)
Brendler CB, Follansbee AL, Isaacs JT (1985) Discrimination between normal hyperplastic and malignant human prostatic tissue by enzymatic profiles. J Urol 133: 495–501
Davies P, Thomas P, Griffith K (1977) Measurement of free and occupied cytoplasmatic and nuclear androgen receptor sites in rat ventral prostate gland. J Endocrinol 74: 393–404
Ellis DW, Leffers S, Stewart Davies J, Ng ABP (1984) Multiple immunoperoxidase markers in benign hyperplasia and adenocarcinoma of the prostate. Am J Clin Pathol 81: 279–284
Frankel AE, Ronse RV, Wang MC (1982) Monoclonal antibodies to a human prostate antigen. Cancer Res 42: 3714–3718
Frankfurt OS, Chin JL, Englander LS (1985) Relationship between DNA-ploidy, glandular differentiation and tumor spread in human prostate cancer Cancer Res 45: 1418–1423
Ford TF, Butcher, DN, Masters JRW, Parkinson MC (1985) Immuncytochemical localisation of prostate-specific antigen: specificity and application to clinical practice. Br J Urol 57: 50–55
Goldenberg DM, Deland FH (1984) Clinical studies of prostatic cancer imaging with radiolabelled antibodies against prostatic acid phosphatase. Urol Clin North Am 11: 277–281
Goldenberg JM, Deland FH, Bewett SJ (1983) Radioimmunodetection of prostatic cancer. In vivo use of radioactive antibodies against prostatic acid phosphatase for diagnosis and detection of prostatic cancer by nuclear imaging. J Am Med Assoc 250: 630–635
Gutman AB, Gutman ED (1938) An acid phosphatase occuring in the serum of patients with metastasizing carcinoma of the prostate gland. J Clin Invest 17: 473–480
Huggins C, Clark PJ (1940) Quantitative studies for prostatic secretion EL The effect of castration and of estrogen injection on the normal and on the hyperplasia prostatic glands of dogs. J Exp Med 72: 7474–758
Huggins C, Hodges CV (1941) Studies on prostatic cancer. 1. The effect of castration, of estrogen and of androgen injection on serum-phosphatases in metastatic cancer of the prostata. Cancer Res 1: 293–297
Lad PH, Cooper JF, Learn DB, Olson CV (1984) Identification of structural and secretary lectin-binding glycoprotein of normal and cancerous human prostate. Biochim Biophys Act Ser Protein Struct Mol Enzymol 791: 186–197
Maatman TJ, Gupta MK, Montie JE (1984) The role of serum prostatic acid phosphatase as a tumor marker in men with advanced carcinoma of the prostate. J Urol 132: 58–60
Pappas AA, Gadsden RH (1984) Prostatic acid phosphatase: clinical utility in detection, assessment and monitory carcinoma of the prostate. Ann Clin Lab Sci 14: 285–291
Pontes JE (1983) Biological markers in prostatic cancer. J Urol 130: 1037–1047
Raynar RH, Hazra TA, Moncure CW, Mohanakumar T (1984) Characterization of a monoclonal antibody K,R P8, that detects a new prostate-specific marker. J Natl Cancer Inst 73: 617–625
Reddy EP (1983) Nucleotide sequence analysis of the T24 human bladder. Carcinoma Oncog Sci 220: 1061–63
Schacht MJ, Garnett JE, Grayhack JT (1984) Biochemical markers in prostatic carcinoma. Urol Clin North Am 11: 253–267
Slaman DJ, DeKernion JB, Verma JM, Cline JM (1984) Expression of cellular oncogenes in human malignancies. Science 224: 256–262
Sukamar S, Pulciani S, Barbacid M (1984) A transforming ras-gene in guinea-pig cell lines initiated by diverse chemical carcinogens. Science 3: 1197–1199
de Voogt HJ, Dinggan P (1978) Steroid receptors in human prostatic cancer. Urol Res 6: 151–155
Webb KS, Wave JL, Parks SF (1983) Monoclonal antibodies to different epitopes on a prostate tumor-associated antigen. Implications for immunotherapy. Cancer Immunol Immunother 14: 155–166
Weinberg RA (1984) Cellular oncogeries. TIBS 4. Elsevier Science, Amsterdam, pp 131–133
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schärfe, T. (1991). Klinisch orientierte Grundlagenforschung. In: Ackermann, R., Altwein, J.E., Faul, P. (eds) Aktuelle Therapie des Prostatakarzinoms. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84264-1_22
Download citation
DOI: https://doi.org/10.1007/978-3-642-84264-1_22
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-84265-8
Online ISBN: 978-3-642-84264-1
eBook Packages: Springer Book Archive